Veeva Systems Automated Data Cleaning for 1 Million Subjects
Clinical trial operators using automated data reconciliation can scale study management as protocol complexity grows.
Updated on Oct. 6, 2026 in Economic Indicators
Veeva Systems has processed data for over 1 million clinical trial subjects using its DQS platform. The tool has supported more than 1,000 studies to date by automating data reconciliation between sites and sponsors.
Why it matters
Automated data management helps operators address the rising volume of clinical trial data and protocol complexity. Adoption of these systems supports compliance with regulatory guidelines like ICH E6(R3), which prioritize risk-based monitoring strategies.
Veeva Systems has cleaned data for 1 million clinical trial subjects and executed 500,000 automated queries across 1,000 studies. The platform currently supports a client base exceeding 1,500 customers.
The players
Veeva Systems
A Public Benefit Corporation providing cloud-based software solutions for the global life sciences industry.
The details
Veeva DQS automates reconciliation between clinical sites and trial sponsors, reducing manual data entry requirements. The Veeva Study Builder Agent further streamlines operations by configuring electronic data capture systems directly from study protocols. These tools collectively manage the increasing complexity of modern trial designs.
Timeline
July 31, 2026: The end of the Veeva Systems fiscal year.
October 6, 2026: Official announcement of the data processing milestones.
October 20-21, 2026: Veeva R&D and Quality Summit in Boston.
Market Landscape
This development follows the industry shift toward risk-based clinical trial management as recommended by the ICH E6(R3) guidelines. It signals an increasing reliance on automated reconciliation to manage protocol complexity.
Operators should review their current trial data workflows to determine if automation can replace legacy manual reconciliation processes. Scaling these systems may help reduce administrative burdens as regulatory requirements for risk-based oversight tighten.
The takeaway
The move toward automated data reconciliation is essential for managing the growing complexity of modern clinical trial protocols. Operators should audit their current trial data systems to ensure compliance with emerging risk-based regulatory standards.
What happens next
The Veeva R&D and Quality Summit is scheduled for October 20-21, 2026, in Boston.
Further reading
Read more on the shift toward digital efficiency in Economic Indicators.
